The prospect of precision therapy for renal cell carcinoma

Chiara Ciccarese, Matteo Brunelli, Rodolfo Montironi, Michelangelo Fiorentino, Roberto Iacovelli, Daniel Heng, Giampaolo Tortora, Francesco Massari

Research output: Contribution to journalReview articlepeer-review


The therapeutic landscape of renal cell carcinoma (RCC) has greatly expanded in the last decade. From being a malignancy orphan of effective therapies, kidney cancer has become today a tumor with several treatment options. Renal cell carcinoma (RCC) is a metabolic disease, being characterized by the dysregulation of metabolic pathways involved in oxygen sensing (VHL/HIF pathway alterations and the subsequent up-regulation of HIF-responsive genes such as VEGF, PDGF, EGF, and glucose transporters GLUT1 and GLUT4, which justify the RCC reliance on aerobic glycolysis), energy sensing (fumarate hydratase-deficient, succinate dehydrogenase-deficient RCC, mutations of HGF/MET pathway resulting in the metabolic Warburg shift marked by RCC increased dependence on aerobic glycolysis and the pentose phosphate shunt, augmented lipogenesis, and reduced AMPK and Krebs cycle activity) and/or nutrient sensing cascade (deregulation of AMPK-TSC1/2-mTOR and PI3 K-Akt-mTOR pathways). In this complex scenario it is important to find prognostic and predictive factors that can help in decision making in the treatment of mRCC.

Original languageEnglish
Pages (from-to)37-44
Number of pages8
JournalCancer Treatment Reviews
Publication statusPublished - Sep 1 2016


  • Clear cell renal cell carcinoma
  • Metastatic renal cell carcinoma
  • mTOR
  • Non-clear cell renal cell carcinoma
  • PD-1
  • PD-L1
  • Personalized medicine
  • Precision medicine
  • Targeted therapy
  • TKI

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'The prospect of precision therapy for renal cell carcinoma'. Together they form a unique fingerprint.

Cite this